|
Shire’s Gaucher Drug Has Edge Over Rival in Trial
Shire’s Gaucher disease drug Vpriv significantly improved lumbar spine bone density, while Sanofi’s Cerezyme did not, according to results from a head-to-head clinical trial presented on Thursday.
Reuters |
Register Now
Archives